US FDA Takes Another Shot At Clarifying Pediatric Study Plan Requirements
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued a revised version of its draft guidance on how drug companies can meet the country's rules on submitting and amending their initial pediatric study plans (iPSPs)1.